These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11444154)

  • 1. Gradual dose taper following chronic buprenorphine.
    Becker AB; Strain EC; Bigelow GE; Stitzer ML; Johnson RE
    Am J Addict; 2001; 10(2):111-21. PubMed ID: 11444154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
    Amass L; Ling W; Freese TE; Reiber C; Annon JJ; Cohen AJ; McCarty D; Reid MS; Brown LS; Clark C; Ziedonis DM; Krejci J; Stine S; Winhusen T; Brigham G; Babcock D; Muir JA; Buchan BJ; Horton T
    Am J Addict; 2004; 13 Suppl 1(Suppl 1):S42-66. PubMed ID: 15204675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low efficacy of non-opioid drugs in opioid withdrawal symptoms.
    Hermann D; Klages E; Welzel H; Mann K; Croissant B
    Addict Biol; 2005 Jun; 10(2):165-9. PubMed ID: 16191669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.
    Northrup TF; Stotts AL; Green C; Potter JS; Marino EN; Walker R; Weiss RD; Trivedi M
    Addict Behav; 2015 Feb; 41():20-8. PubMed ID: 25282598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers.
    Woodcock EA; Lundahl LH; Greenwald MK
    Drug Alcohol Depend; 2015 Jan; 146():89-96. PubMed ID: 25479914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.
    Dunn KE; Sigmon SC; Strain EC; Heil SH; Higgins ST
    Drug Alcohol Depend; 2011 Dec; 119(1-2):1-9. PubMed ID: 21741781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.
    Strain EC; Stitzer ML; Liebson IA; Bigelow GE
    J Clin Psychopharmacol; 1996 Feb; 16(1):58-67. PubMed ID: 8834420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanded table: Some drugs for management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):e144-e146. PubMed ID: 30133422
    [No Abstract]   [Full Text] [Related]  

  • 9. Characterizing opioid withdrawal during double-blind buprenorphine detoxification.
    Dunn KE; Saulsgiver KA; Miller ME; Nuzzo PA; Sigmon SC
    Drug Alcohol Depend; 2015 Jun; 151():47-55. PubMed ID: 25823907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):137-141. PubMed ID: 30133420
    [No Abstract]   [Full Text] [Related]  

  • 12. Buprenorphine tapering schedule and illicit opioid use.
    Ling W; Hillhouse M; Domier C; Doraimani G; Hunter J; Thomas C; Jenkins J; Hasson A; Annon J; Saxon A; Selzer J; Boverman J; Bilangi R
    Addiction; 2009 Feb; 104(2):256-65. PubMed ID: 19149822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergency management of inadvertent accelerated opiate withdrawal in dependent opiate users.
    Lubman D; Koutsogiannis Z; Kronborg I
    Drug Alcohol Rev; 2003 Dec; 22(4):433-6. PubMed ID: 14660133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing Opioid Withdrawal in the Emergency Department With Buprenorphine.
    Herring AA; Perrone J; Nelson LS
    Ann Emerg Med; 2019 May; 73(5):481-487. PubMed ID: 30616926
    [No Abstract]   [Full Text] [Related]  

  • 15. Less pain, more gain: buprenorphine-naloxone and patient retention in treatment.
    Renzelli CM; Capretto NA
    J Addict Dis; 2006; 25(3):97-104. PubMed ID: 16956874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients.
    Eissenberg T; Johnson RE; Bigelow GE; Walsh SL; Liebson IA; Strain EC; Stitzer ML
    Drug Alcohol Depend; 1997 Apr; 45(1-2):81-91. PubMed ID: 9179510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.
    Fudala PJ; Yu E; Macfadden W; Boardman C; Chiang CN
    Drug Alcohol Depend; 1998 Mar; 50(1):1-8. PubMed ID: 9589267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users.
    Nielsen S; Hillhouse M; Thomas C; Hasson A; Ling W
    J Addict Med; 2013; 7(1):33-8. PubMed ID: 23222095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.